ICONIC-ASCEND: Icotrokinra Tops Placebo, Matches Ustekinumab in Psoriasis
Johnson & Johnson's icotrokinra (Icotyde) outperformed placebo and was noninferior to ustekinumab in a phase 3 trial for moderate to severe plaque psoriasis. At week 16, 55.2% of patients on icotrokinra achieved PASI 90 vs. 3.6% on placebo. At week 28, icotrokinra was noninferior to ustekinumab, with numerically higher response rates but no statistical superiority. The drug is already approved in the US, Europe, Japan, and China.
How this was made
The 30-second read
Why it matters
The trial met co-primary endpoints with 55.2% PASI‑90 vs 3.6% placebo and showed noninferiority to ustekinumab, suggesting a viable oral alternative.
Market read
First‑time reporting of Phase 3 data for an oral psoriasis therapy; likely to move J&J stock and influence the broader dermatology market.
What to watch
Potential reimbursement or pricing challenges could temper upside.
Background
Johnson & Johnson's icotrokinra is the first oral IL‑23 inhibitor for moderate to severe plaque psoriasis, competing with injectable biologics.
Ticker impact
Johnson & Johnson announced topline Phase 3 ICONIC-ASCEND trial results showing icotrokinra met primary endpoints and was noninferior to ustekinumab.
likely upward pressure as market prices in the favorable efficacy results
First disclosure of Phase 3 data for a new oral IL‑23 inhibitor; investors typically react positively to successful late‑stage trials.
Market effects
Strengthens the psoriasis treatment segment and may pressure competing biologics.
US biotech sector could see modest gains.
Highlights oral peptide approach, relevant to global pharma pipelines.
Counterpoint
If investors doubt oral delivery advantages, the data may be priced out quickly.
Key entities
- CompanyJohnson & Johnson
Manufacturer of icotrokinra and sponsor of the ICONIC-ASCEND trial.
- DrugUstekinumab
Injectable comparator biologic in the trial.
